Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2013 Nov 9:13:58.
doi: 10.1186/1471-2490-13-58.

Treatment patterns and characteristics of European patients with castration-resistant prostate cancer

Cora N Sternberg  1 , Edwina S Baskin-Bey, Mark Watson, Andrew Worsfold, Alex Rider, Bertrand Tombal
Affiliations
Multicenter Study

Treatment patterns and characteristics of European patients with castration-resistant prostate cancer

Cora N Sternberg et al. BMC Urol. .

Abstract

Background: European treatment guidelines recommend the use of hormonal therapy for the treatment of advanced prostate cancer, including castration-resistant prostate cancer (CRPC), but there is little understanding of how common practices in prostate cancer treatment compare across Europe. The aim of this analysis was to evaluate the management of CRPC patients across five European countries (France, Germany, Italy, Spain and the UK).

Methods: Data were drawn from the Adelphi Real World Prostate Cancer Disease Specific Programme (DSP), a cross-sectional survey of patients undertaken between December 2009 and May 2010. The study is based on physician interviews, physician-completed detailed patient record forms, and a patient-completed questionnaire.

Results: A total of 348 physicians (191 urologists and 157 oncologists) reported on 3477 patients with prostate cancer. Of the 3477 patients, 1405 (40%) were categorised as having CRPC, and 1119 of these had metastatic CRPC. Bone metastases were the most common (78%), followed by liver (37%) and lung (30%). The mean age of CRPC patients was 71 years, 35% were current or ex-smokers and 10% had a family history of prostate cancer. CRPC patients had a mean of 1.8 comorbidities; 66% had hypertension and 32% had diabetes. Most physicians estimated their patients would stop responding to initial hormone therapy after 19-24 months. Overall, addition of an anti-androgen to a luteinising-hormone-releasing hormone (LHRH) agonist was the most commonly prescribed therapy when patients failed initial LHRH agonist therapy, although there were considerable variations between countries. While 72% of physicians in Europe would choose chemotherapy as the next treatment option after diagnosis of CRPC, 31% of this group would initially prescribe this without an LHRH agonist.

Conclusions: Results from this analysis highlight inconsistencies in common hormonal therapy treatment patterns for CRPC and hormonal therapy across the EU.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mean daily number of patients diagnosed <6 months seen by physicians by stage of disease.
Figure 2
Figure 2
Mean physician-stated time until prostate cancer progresses despite ADT use.
Figure 3
Figure 3
Treatment patterns for patients receiving their first chemotherapy.
See this image and copyright information in PMC

References

    1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46:765–781. doi: 10.1016/j.ejca.2009.12.014. - DOI - PubMed
    1. CancerStats Prostate Cancer Incidence Statistics. http://www.cancerresearchuk.org/cancer-info/cancerstats/types/prostate/i.... Accessed Oct 2012.
    1. Akaza H. Combined androgen blockade for prostate cancer: review of efficacy, safety and cost-effectiveness. Cancer Sci. 2011;102:51–56. doi: 10.1111/j.1349-7006.2010.01774.x. - DOI - PubMed
    1. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, Mason MD, Matveev V, Mottet N, Van der Kwast TH, Wiegel T, Zattoni F. EAU guidelines on prostate cancer. http://www.uroweb.org/gls/pdf/08%20Prostate%20Cancer_LR%20March%2013th%2.... Accessed Oct 2012. - PubMed
    1. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, der KT V, Wiegel T, Zattoni F. et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2011;59:572–583. doi: 10.1016/j.eururo.2011.01.025. - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources